ArticleSkin health and disease2026
ALADIN (Acne Lesion And Density INdex): a novel tool for automatic acne severity assessment.
Article in Skin health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acne affects approximately 80% of adolescents worldwide, regardless of age, sex or ethnicity. Effective treatment depends on timely and accurate severity assessment. However, the lack of methodological standardization results in high inter- and intraobserver variability. A standardized and explainable grading tool is needed to support consistent acne severity evaluation. Objectives: To develop an artificial intelligence-driven tool that quantifies inflammatory lesion count and density from facial images to calculate scores aligned with the Investigator Global Assessment (IGA) scale. Methods: ALADIN (Acne Lesion And Density INdex) is designed as a simple mathematical model able to deliver reproducible and interpretable acne severity scores. We validated ALADIN retrospectively using two datasets: (i) a public dataset with predominantly severe cases of acne and (ii) a private dataset of mild-to-moderate cases. Validation results evaluated ALADIN against IGA and Global Acne Grading System (GAGS) scores, annotated by expert dermatologists. Results: Lesion detection with ALADIN was evaluated using precision, recall, mean average precision and mean absolute error (MAE). Acne grading performance was assessed via Pearson/Spearman correlations, MAE and Cohen's kappa. ALADIN's performance aligned well with the interobserver correlation of dermatologists, achieving Pearson correlations of 0.58 vs. 0.56 and 0.65 vs. 0.65 (private and public datasets, respectively) for IGA scores, and 0.32 vs. 0.44 and 0.43 vs. 0.44 for GAGS scores. Conclusions: ALADIN demonstrates consistent performance and excellent interpretability. Compared with manual scoring systems, it provides a streamlined, data-driven alternative capable of minimizing observer bias. When integrated into a medical device software, it can further aid in standardizing acne severity assessment and enhance patient monitoring. However, in this study, analyses were predominately carried out with White and Asian patients. Future work will validate and ensure robustness with darker skin tones.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.